Skin expression data from psoriasis patients treated with the HSP90 inhibitor RGRN-305

HSP90 is a downstream regulator of TNFα and IL-17A signaling and may therefore serve as a novel target in the treatment of psoriasis. We assessed global gene expression by microarray analysis to explore the molecular transformation in skin samples from psoriatic patients during treatment with the HSP90 inhibitor RGRN-305. Skin punch biopsies were taken from nonlesional (NL) and lesional (LS) psoriatic skin of 13 psoriatic patients before treatment and from lesional psoriatic skin at 4, 8, and 12 weeks during HSP90 inhibitor treatment. RNA was extracted from the skin biopsies and used for microarray analysis.